Data demonstrating the effectiveness of the combination of cancer immunotherapies are being disclosed. Recently, Opdivo+Yerboy therapy has been shown to improve the survival duration when used as a first-line treatment of hepatocellular carcinoma (HCC). GI Innovation confirmed partial response (PR) using cancer immunotherapies as combination therapy in clinical trials. TiumBio also observed cancer cell death in various solid tumors, including pancreatic cancer, anal cancer, and lung cancer. AptaBio is assessing the potential of cancer immunotherapy Keytruda as a combination therapy.

According to industry sources on July 31st, Bristol Myers Squibb (BMS) has recently applied to the European Medicines Agency